If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
==== Issue of self-determination and Russian meddling ==== The report also concluded that South Ossetia and Abkhazia did not have a right to secede from Georgia (which they did in the early 1990s), because according to the uti possidetis principle, only constituent republics such as Georgia, but not territorial sub-units such as South Ossetia or Abkhazia had the right to independence during the breakup of the Soviet Union. Their recognition was "consequently contrary to international law." The commission concluded, "South Ossetia came close to statehood without quite reaching the threshold of effectiveness. It was – from the perspective of international law – thus not a state-like entity, but only an entity short of statehood." Abkhazia "might be seen to have reached the threshold of effectiveness. It may therefore be qualified as a state-like entity." However, the commission stressed that "the Abkhaz and South Ossetian claims to legitimacy are undermined by the fact that a major ethnic group (i.e.
In 1994, world production of H2O2 was around 1.9 million tonnes and grew to 2.2 million in 2006, most of which was at a concentration of 70% or less. In that year, bulk 30% H2O2 sold for around 0.54 USD/kg, equivalent to US$1.50/kg (US$0.68/lb) on a 100% purity basis. Hydrogen peroxide is manufactured almost exclusively by the anthraquinone process, which was originally developed by BASF in 1939. It begins with the reduction of an anthraquinone (such as 2-ethylanthraquinone or the 2-amyl derivative) to the corresponding anthrahydroquinone, typically by hydrogenation on a palladium catalyst. In the presence of oxygen, the anthrahydroquinone then undergoes autoxidation: the labile hydrogen atoms of the hydroxy groups transfer to the oxygen molecule, to give hydrogen peroxide and regenerating the anthraquinone. Most commercial processes achieve oxidation by passing compressed air through a solution of the anthrahydroquinone, with the hydrogen peroxide then extracted from the solution and the anthraquinone recycled back for successive cycles of hydrogenation and oxidation. The net reaction for the anthraquinone-catalyzed process is:
Unsafe in porphyria. Caution when used in patients with epilepsy; Parkinson's disease; narrow angle glaucoma; prostatic hypertrophy; hypothyroidism; hyperthyroidism; liver disease; cardiac disease or arrhythmias; severe respiratory disease; renal failure; myasthenia gravis; phaeochromocytoma. Patients with hypersensitivity to thioxanthenes or other antipsychotics. Close monitoring for changes in behaviour, suicidal thoughts or clinical worsening during the initial part of the treatment is recommended. May impair control of diabetes; monitor blood glucose in diabetics. Drowsiness, dry mouth, constipation, vomiting, dyspepsia, diarrhea, abdominal pain, nausea, flatulence. Extrapyramidal effects, especially in the initial phase of the treatment. Tachycardia, palpitations, prolonged QT interval, hypotension. Thrombocytopenia, neutropenia, leukopenia, agranulocytosis. Dyspnoea, myalgia, muscle rigidity, micturition disorder, urinary retention. Increased appetite and weight. Abnormal glucose tolerance and LFTs. Insomnia, depression, nervousness, agitation, decreased libido, Tardive dyskinesia.
=== March === 11 March – Clive Revill, actor (The Empire Strikes Back, Irma La Douce, Oliver!) (born 1930). 13 March – Brian McMahon, venereologist, army officer, medical superintendent (Wakari Hospital, Dunedin Hospital) and lecturer (University of Otago) (born 1929). 14 March – Anne Nightingale, nurse, chair of the Nursing Council (1975–1984) (born 1932). 16 March – Gordon H. Brown, art historian, gallery director (Waikato Art Gallery, Sarjeant Gallery), and artist (born 1931). 20 March – Matt Mitchell, sailor (Team New Zealand, Alinghi, Oracle Team USA) (born c. 1971). 21 March – Nick Carter, lawyer and judge, Māori Land Court judge (1989–2002) (born 1935). 22 March – Alex Wyllie, rugby union player (Canterbury, national team) and coach (Canterbury, national team, Argentina) (born 1944). 31 March Sir Roger Clifford, 7th Baronet (born 1936). Ron Jones, obstetrician and gynaecologist (National Women's Hospital, University of Auckland), whistleblower in the "Unfortunate Experiment" (born 1939).
Sources: en.wikipedia.org
This article incorporates text by Laura J. Cobb, Changhan Lee, Jialin Xiao, Kelvin Yen, Richard G. Wong, Hiromi K. Nakamura, Hemal H. Mehta, Qinglei Gao, Carmel Ashur, Derek M. Huffman, Junxiang Wan, Radhika Muzumdar, Nir Barzilai, and Pinchas Cohen2 available under the CC BY 4.0 license.
2-Hydroxy-4,5-methylenedioxymethamphetamine (6-hydroxy-3,4-methylendioxymethamphetamine) It is a non-neurotoxic metabolite of the drug 3,4-methylenedioxymethamphetamine, structurally related to 2-hydroxy-4,5-methylenedioxyamphetamine; it is detected in the brains and plasma of rats but not in their urine. It did not alter the levels of norepinephrine, glutathione, glial fibrillary acidic protein, or serotonin.
Flavoring are often added to e-liquids as well as dry smoke blends. There are currently over 7,700 e-liquid flavors available, most have not been laboratory tested for toxicity. There are numerous flavors (e.g., fruit, vanilla, caramel, coffee) of e-liquid available. There are also flavorings that resemble the taste of cigarettes.
dosage compensation Any mechanism by which organisms neutralize the large difference in gene dosage caused by the presence of differing numbers of sex chromosomes in the different sexes, thereby equalizing the expression of sex-linked genes so that the members of each sex receive the same or similar amounts of the products of such genes. An example is X-inactivation in female mammals.
As a prototypical transaminase, AST relies on PLP (vitamin B6) as a cofactor to transfer the amino group from aspartate or glutamate to the corresponding ketoacid. In the process, the cofactor shuttles between PLP and the pyridoxamine phosphate (PMP) form. The amino group transfer catalyzed by this enzyme is crucial in both amino acid degradation and biosynthesis. In amino acid degradation, following the conversion of α-ketoglutarate to glutamate, glutamate subsequently undergoes oxidative deamination to form ammonium ions, which are excreted as urea. In the reverse reaction, aspartate may be synthesized from oxaloacetate, which is a key intermediate in the citric acid cycle.
Sources: en.wikipedia.org
== Bioanalytical organisations == There are several national and international bioanalytical organisations active throughout the world. Often they are part of a bigger organisation, e.g. Bioanalytical Focus Group and Ligand Binding Assay Bioanalytical Focus Group, which are both within the American Association of Pharmaceutical Scientists (AAPS) and FABIAN, a working group of the Analytical Chemistry Section of the Royal Netherlands Chemical Society. The European Bioanalysis Forum (EBF), on the other hand, is independent of any larger society or association.
Thymosin beta-4, Y-chromosomal is a protein that in humans is encoded by the TMSB4Y gene. The protein consists (in humans) of 44 amino acids (msdkpgmaei ekfdksklkk tetqeknpls sketieqerq ages) MolWt 4881.
From the late 1960s to the early 1970s, with the rapid surge in recreational drug use in the U.S., the production of narcotics in Mexico, particularly marijuana, expanded exponentially, and Mexican criminals started to smuggle drugs on a major scale. During the 1960s and 1970s, Mexico participated in a series of U.S.-backed anti-narcotics initiatives, including Operation Intercept and Operation Condor. These operations were formally justified on the grounds of combating the cultivation of opium poppies and marijuana in Mexico's so-called "Golden Triangle" region, an area encompassing parts of the states of Sinaloa, Durango, and Chihuahua. As part of the campaign, the Mexican government deployed about 10,000 soldiers and police. The operation resulted in mass arrests, torture, and imprisonment of peasants who were often accused of aiding leftist insurgency groups, but no major traffickers were captured. Contemporary assessments deemed the initiatives a failure, citing their inability to curb narcotics production, enabling military corruption, and their record of human rights abuses in rural areas. As U.S. efforts in the war on drugs intensified, crackdowns in Florida and the Caribbean during the Miami drug war forced Colombian traffickers to develop new routes for smuggling cocaine into the United States. By the early 1980s, the Medellin Cartel and Cali Cartel oversaw production, while distribution increasingly relied on Mexican traffickers.
Light oils (turpentine): Oils lighter than water that rise to the top. Pitch or tar: The heavy, nearly solid residue left at the bottom. Heavy oils (creosote): These are the "oils heavier than water." This specific fraction is the medical or industrial creosote, valued for its preservative and antiseptic properties.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.